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Plasma and inflammatory fluid kininogen levels, and blood and inflammatory fluid free kinin levels were 
determined in rats 24 h after the injection of carrageenin into an air pouch. Plasma T-kininogen levels in- 
creased 7-fold. In the inflammatory fluid levels reached 8pg/ml. Blood levels of free kinin showed a 5-fold 
increase. The kinins were identified on HPLC as T-kinin (Ile-Ser-bradykinin) and bradykinin, 63 and 37x, 
respectively. These results indicate for the first time that free T-kinin as well as bradykinin is released during 
an inflammatory esponse inrat and confirms our previous finding that T-kininogen may be a major acute- 
phase protein in inflammation. 
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1. INTRODUCTION 
T-kininogen, which contains the phar- 
macologically active T-kinin molecule (Ile-Ser- 
bradykinin), has been shown by our laboratory to 
be highly elevated in the plasma of rats with adju- 
vant arthritis [l]. This is most significant since T- 
kininogen has now been identified as a major acute 
inflammatory protein [2]. In this investigation we 
studied the major question whether T-kinin itself is 
released in an inflammatory condition. We also 
determined whether bradykinin itself is released. 
Carrageenin was used to induce an inflammation 
in an air pouch in the rat. The subsequent fluid ac- 
cumulation allowed for the study of the various 
kininogens and free kinins in the fluid as well as in 
plasma and blood of normal and animals re- 
sponding to carrageenin. 
2. MATERIALS AND METHODS 
2.1. Carrageenin air-pouch 
6-week-old male Sprague-Dawley rats (160- 
180 g) were used. The method of Fukuhara and 
Tsurufuji [3] was used to induce a carrageenin air- 
pouch inflammation. Rats were injected sub- 
cutaneously at the dorsum with 8 ml air to make 
an air pouch. After 24 h, 4 ml of 2% carrageenin 
solution (sterilized) containing penicillin G 
(0.1 mg/ml) and streptomycin sulfate (0.1 mg/ml) 
was injected into the pouch (day 0). 
2.2. Collection of blood, plasma and 
inflammatory fluid 
24 h after the carrageenin solution injection, 
blood samples were collected from 5 rats under 
light ether anesthesia. Two samples were drawn 
from the abdominal aorta of each rat into two 
separate polyethylene syringes connected to a 
3-way stopcock. The first sample was collected in 
a 1 ml syringe containing 0.1 ml of 3.8% sodium 
citrate and was used for kininogen determinations. 
The second sample was collected in a 10 ml syringe 
containing 5 ml of 30% trifluoroacetic acid (TFA) 
and was used to measure the concentration of free 
kinins. Inflammatory fluid from the pouch was 
collected in a plastic container. 0.5 ml of this fluid 
was transferred to a polyethylene tube containing 
0.05 ml of 3.8% sodium citrate (for kininogen 
determination). The remaining fluid was im- 
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mediately (within 2-3 s) mixed with an equd 
volume of 30% TFA (for free kinin deter- 
mination). 
2.3. Assay of kininogen and free kinin levels 
Plasma and inflammatory fluid T-kininogen 
were determined as described [l]. The procedure 
involves pretreatment of the plasma and/or in- 
flammatory fluid with HCl and conversion of the 
T-kininogen to T-kinin by an excess amount of 
trypsin, followed by radioimmunoassay of the 
released kinin 141. For high%, kininogen deter- 
minations, the plasma and the inflammatory fluids 
were shaken with glass powder to activate 
kallikrein which releases bradyki~n from high% 
kininogen. The released bradykinin was deter- 
mined by radioimmunoassay. The level of low-M, 
kininogen was calculated by subtracting the con- 
centrations of high-A.& kininogen and T-kininogen 
from the concentration of total kininogen {total 
amount of kinin released by excess amount of tryp- 
sin). Free kinins in the TFA-treated blood and in- 
~~matory fluid were determined following cen- 
trifugation at 5000 x g for 10 min of the TFA 
precipitate. The supernatants were then applied to 
a Crs-extraction column (1 x 2 cm), previously 
primed with 5 ml methanol and 5 ml of 1% TFA. 
After washing the column with 5 ml of 1% TFA, 
kinins were eluted with 3 ml of 50% acetonitrile in 
1% TFA. The eluate was evaporated and redis- 
solved in 200 ~1 distilled water. Kinins extracted 
from the blood and the fluid were separated by a 
reverse-phase HPLC as in [S]. The fractions were 
collected and evaporated. The residue was 
redissolved in the buffer and radioim- 
munoassayed. The results were corrected in accor- 
dance with the recovery percentage (70% through 
all steps). 
2.4. Materials 
The sources were: carrageenin (Seakem no.202, 
Marine Colloid); trypsin (type X1 I, TPCK-treated 
from bovine pancreas, Sigma); bradykinin, [Tyr I]- 
kallidin (Peninsula Corp.); Na”‘I (carrier-free, 
New England Nuclear); octadecyl-extraction coi- 
umn (J.T. Baker). T-kinin (Ile-Ser-bradykinin) 
was synthesized and supplied by courtesy of Dr 
J.M. Stewart (Department of Biochemistry, 
University of Colorado Health Science Center). 
3. RESULTS 
Table 1 illustrates the levels of kinins and 
kininogens in plasma, blood and in~~matory 
fluid of normal and experimental animals 
(carrageenin-treated). It may be seen that free T- 
kinin as well as bradykinin appear to be elevated in 
all fluids 24 h after the carrageenin injection 
(about 4-5-fold). Similarly, free T-kinin and 
bradykinin appear in the inflammatory fluid 24 h 
after the injection. 
The level of T-kininogen was increased some 
7-fold in plasma after 24 h following the car- 
rageenin injection; high-M, kininogen on the other 
Table 1 
Kininogen and kinin levels of rats treated with 
carrageenin 
Kininogen and 
kinin levels 
Day after carrageenin injection 
Day 0 Day 1 
Plasma 
T-kininogen 
(,zg BK equiv./ml) 
~igh-~~ kininogen 
@g BK equiv./ml) 
Low-M, kininogen 
kg BK equiv./ml) 
Blood 
T-kinin (ng/ml) 
Bradykinin (ng/ml) 
WI ammatory fluid 
Fluid volume (ml) 
T-kininogen 
@g BK equiv./ml) 
High-M, kininogen 
kg BK equiv./ml) 
Low-M, kininogen 
kg BK equiv./ml) 
T-kinin (ng/ml) 
Bradykinin (ng/ml) 
5.04 + 1.56 36.99 rt 5.34 
0.82 * 0.06 1.04 rt 0.04 
0.96 -t 0.09 0.91 rf: 0.10 
0.053 * 0.031 0.265 + 0.067 
0.037 + 0.010 0.153 * 0.021 
- 6.75 -t 0.34 
- 8.48 I 1.11 
- 0.05 + 0.01 
- 0.78 ziz 0.17 
- 0.340 rt 0.072 
- 0.134 rt 0.040 
Plasma and inflammatory fhrid kininogen levels, and 
blood and inflammatory fluid free kinin levels were 
measured 24 h after the injection of carrageenin. The 
results were calculated after HPLC analysis followed by 
radioimmunoassay. Each value indicates a mean value 
of 5 rats f SE 
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Fig. -1. Reverse-phase HPLC of immunoreactive free 
kinins from the plasma of normal (M) and 
carrageenin-treated (@-+) rats. Kinin in each fraction 
was assayed by radioimmunoassay using bradykinin as a 
standard. 
hand showed little change. The inflammatory fluid 
itself contained as its major kininogen, T- 
kininogen. 
Fig.1 confirms by HPLC procedures the 
presence of free T-kinin and bradykinin in normal 
rat blood and their elevation 24 h after carrageenin 
injection. 
4. DISCUSSION 
Recently Okamoto and Greenbaum [6-81 
discovered in rat plasma a kininogen which con- 
tained the novel sequence Ile-Ser-bradykinin and 
which they called T-kininogen. Barlas et al. [l] 
showed that plasma T-kininogen is the major 
plasma kininogen of the rat and increases 15-fold 
in rats with adjuvant arthritis. Other kininogens, 
high-M, kininogen and low-M, kininogen, showed 
little or no change under these conditions. Here, 
we have confirmed that T-kininogen is of major 
importance in the inflammatory response; plasma 
levels increased 7-fold, 24 h after the carrageenin 
injection while no detectable change occurred in 
high-M, and/or low-M, kininogens. It is of signifi- 
cant interest that Cole et al. [2] have described the 
major acute-phase m-protein of the rat as a 
kininogen. We note that this kininogen contains 
the sequence of T-kinin and therefore is T- 
kininogen. 
Heretofore, bradykinin has generally been 
thought to be the only kinin mediator released 
in the inflammatory response. Our results 
demonstrate for the first time that T-kinin appears 
in free form in blood and fluids of rats following 
an inflammatory challenge. The appearance of 
bradykinin is also observed. Whether bradykinin is 
released directly or is a consequence of T-kinin 
metabolism is unknown at this time. Since 
kallikreins do not release T-kinin from T- 
kininogeii, the appearance of T-kinin indicates 
that an enzyme system other than kallikreins is pre- 
sent in rat blood or tissues and is activated to 
release T-kinin during inflammation. Whether this 
enzyme is cathepsin D or an enzyme yet to be 
described is under study. The T-kinin-T-kininogen 
system is obviously of major importance in the in- 
flammatory challenge since it releases a potent 
vasoactive mediator (T-kinin) and acts as a major 
acute-phase protein. 
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